drugset / Trial / NCT00864175
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single arm, modified dose escalation, open label trial with the objectives of: (1) Determining a safe optimal dose of INCB007839 in combination with trastuzumab and docetaxel (2) Determining clinical efficacy and safety of INCB007839 in combination with trastuzumab and docetaxel.
Timeline
- Start
- 2007-07
- Primary completion
- 2011-06
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADERBASIB | Small molecule | 100 mg | — |
| Subject | ADERBASIB | Small molecule | 200 mg | — |
| Subject | ADERBASIB | Small molecule | 300 mg | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |